2021年2月28日星期日

Thai medical glove maker invests $1.6bn to triple capacity by 2026

 


Sri Trang Gloves' net profit jumps twentythreefold on pandemic-led demand

As the coronavirus spread, demand for medical-use gloves grew among health care professionals as well as restaurant servers and other service sector employees.   © Reuters

BANGKOK -- Sri Trang Gloves Thailand posted a record net profit in 2020 as the COVID-19 pandemic led to a huge increase in demand for the company's protective gear, persuading it to invest 48 billion baht ($1.6 billion) to triple its capacity by 2026.

Strong demand for medical-use gloves translated to a nearly twentythreefold expansion in net profit, to an all-time high of 14.4 billion baht. Sri Trang Gloves' revenue increased 2.5 times to a record high of 30.4 billion baht.

The company, which in June debuted on The Stock Exchange of Thailand, has upwardly revised its previous plan to increase production. Under the new plan, the company will ramp up capacity to 50 billion gloves next year and to 100 billion in 2026. It currently has a 32 billion-glove capacity.

"[G]loves have become an essential part of personal protective equipment not only in the health care and industrial sectors but also for other, new users," the company said in a statement. The robust growth in demand combined with a limited production capacity and a scarcity of raw materials has driven selling prices up, the company added.

Sri Trans' record financial results came after Malaysia-based Top Glove, the world's largest rubber glove producer, posted a twentyfold year-on-year jump in net profit, to 2.4 billion ringgit ($590 million), for the quarter ended November.

The demand surge shows no sign of abating. "Our order backlog currently extends to 13 months for NR (natural rubber) gloves and 30 months for NBR (nitril-butadiene rubber) gloves, even though we are on track to have additional capacity in every quarter of 2021," Sri Trang Gloves said.

The Malaysian Rubber Glove Manufacturers Association projects demand for medical-use gloves this year to expand at a rate of around 15% to 20%, to 420 billion pieces.

"Doctors still need to wear gloves while they give us vaccine shots," an analyst at Asia Plus Securities said. "Meanwhile, it's not only medical personnel who need these gloves; you can see waiters in restaurants wearing them now that COVID has completely set up a new normal for us."

Thailand is the world's biggest producer of natural rubber, harvesting around 4.7 million tons a year. Easy and inexpensive access to the critical raw material has given Sri Trang Gloves a competitive advantage in the global market.

The company last year invested some of the funds it raised through its initial public offering to increase its annual capacity to 32 billion gloves, up from 27 billion, at its four factories in southern Thailand, an area responsible for around 80% of the country's total rubber output.

Sri Trang Gloves' record performance inflated the financial results of its parent, Sri Trang Agro Industry, which is also listed on the SET and holds a 50.2% stake in Sri Tang Gloves. The parent posted a record 9.5 billion baht net profit for 2020, after having suffered a 148 million baht net loss the previous year.

2021年2月24日星期三

Baffling shareholding changes at ES Ceramics

 


This article first appeared in The Edge Malaysia Weekly, on February 15, 2021 - February 21, 2021.
Baffling shareholding changes at ES Ceramics

MARKET talk has it that ES Ceramics Technology Bhd may have a new substantial shareholder but details were scarce at press time. The recent shareholding changes at the company are perplexing, to say the least.

Filings on shareholding changes with Bursa Malaysia show that Tan San Kwang, son of ES Ceramics’ non-independent, non-executive director, Datuk Kamal Y P Tan, acquired 47 million shares or 10.2% in the company on Jan 29, for almost 58 sen per share or RM27.23 million.

Also on Jan 29, Kamal acquired 25 million shares (5.43%) at 58 sen per share (RM14.48 million) and sold it later in the day at the same price.

In a nutshell, Kamal via San Kwang acquired 10.2% in ES Ceramics, but also bought and sold another 5.43% in the company on the same day.

Kamal ceased to be a substantial shareholder in ES Ceramics in early November last year after selling 20.74% in the company. The question then was who the buyer was, as no new substantial shareholder controlling more than 5% equity interest surfaced — until now.

So, what is going on?

“It’s confusing, I don’t understand what’s happening,” one veteran market watcher says. Another seasoned market observer agrees that it does not make sense. “I don’t understand (enough) to comment on what he (Kamal) is doing.”

While all this has been going on, an individual, Rosli Hamat, has emerged as a substantial shareholder in the company after acquiring 24.55 million shares, or 5.33%, on Jan 27.

The notice that Rosli had become a substantial shareholder was made on Feb 4, the same day San Kwang surfaced and Kamal bought and sold the substantial stake in ES Ceramics.

Who is Rosli, and does he have any links to Kamal?

Another pressing question is why Kamal sold his 20.74% last November and, three months later, acquired a 5.43% stake only to sell it on the same day. And why didn’t he just transfer his shares to his son last November?

This is also a good time for ES Ceramics as its business is likely to boom. The company, which makes ceramic formers for rubber glove makers, has been among the beneficiaries of the Covid-19 pandemic.

This also raises questions as to why Kamal sold out of ES Ceramics in November when the company was likely to have a good run in earnings.

When he sold his stake then, ES Ceramics was trading at about 60 sen. Its share price shot up in late January this year, and climbed as high as 77.5 sen on Feb 8. It closed last Tuesday at 74.5 sen, translating into a market capitalisation of RM343 million.

ES Ceramics’ share price gained more than 220% in late July to early August last year. In late September to early October, it surged again, by more than 50%. On both occasions, the dips in the shares were as swift as the gains.

Attempts by The Edge to reach Kamal were unsuccessful.

Kamal’s assets

High-level executives of Singapore-listed Envictus International Holdings Ltd, for which Kamal is non-executive director and adviser, said it is difficult to contact him as he is “semi-retired”.

Companies under Envictus include Pok Brothers Sdn Bhd, which imports frozen foodstuff; Texas Chicken (Malaysia) Sdn Bhd and San Francisco Coffee Sdn Bhd.

A check with Envictus’ 2020 annual report indicates that as at Jan 11, 2021, Kamal and his brother Datuk Jaya J B Tan had 35.91% equity interest in the company. Envictus has a market cap in excess of S$31.65 million.

Envictus was previously known as Etika International Holdings Ltd, but changed its name after selling its dairy business in mid-2014 to Japan’s Asahi Group for more than RM1 billion.

Kamal has a 20.51% stake in Singapore-listed Lasseters International Holdings Ltd. He is a non-executive director of the company, which owns and operates a resort with gaming and hospitality offerings in Alice Springs, Northern Territory, as well as spa and wellness retreat businesses in Hunter Valley, New South Wales, in Australia, and a property development business in Malaysia.

Lasseters has a market cap of more than S$18 million.

The Edge also tried to reach Kamal through ES Ceramics, but did not get a response.

For the six months ended November last year, ES Ceramics registered net profits of RM7.21 million from RM27.53 million in revenue. Compared with the previous corresponding period, net profits were up by 253%, while revenue strengthened by 55.52%.

In notes accompanying its financials, ES Ceramics attributes the better numbers to “higher sales output from the additional production capacity due to strong demand of formers, improved production activities and higher selling price”.

As at end-November 2020, ES Ceramics had cash and cash equivalents of RM48.12 million and total debts of about RM230,000. It also had retained profits of RM26.59 million.

ES Ceramics has a plant in Kawasan Perindustrian Silibin, Ipoh, Perak, and another facility in Songkhla, Thailand. According to its website, the company was established in 1998, producing formers for examination gloves, but has since expanded to make formers for surgical, household and industrial gloves and balloons, among others.

A former is a ceramic mold, dipped into latex to manufacture rubber gloves, giving the glove the requisite shape.

The acquisition of this plant in Thailand by Kamal has resulted in legal disputes.

Longstanding dispute

In October 2019, a bankruptcy hearing against Kamal was advertised in a local paper, which The Edge understands has been disputed by him.

The creditor is Ong Yew Teik, the original owner of Thailand-based Euroceramic Technology Co Ltd (ECT), which Kamal acquired.

Ong is understood to have sold his 82.17% stake in ECT to Kamal for RM8.02 million in 2006 and based on court documents, he is claiming for the sum as it was purportedly not paid.

What is going on is unclear, as most would think that RM8 million is unlikely to leave a dent in corporate player Kamal’s coffers.

In mid-2008, Kamal and minority shareholders sold ECT to ES Ceramics for RM8 million cash. According to the circular to shareholders back then, his share of the RM8 million was RM6.57 million.

According to ES Ceramics’ announcements to Bursa Malaysia, the acquisition of ECT was concluded on Sept 15, 2008. Fillings with the bourse indicate that on Sept 29, 2008, Kamal acquired 6.06 million shares in ES Ceramics for an 11.44% stake in the company. In February the following year, he was appointed a non-independent non-executive director of ES Ceramics. By the time he was appointed to the board, he had accumulated 13.31 million shares or 25.13% in the company.

However, based on court documents, Ong is understood to be seeking financial compensation, and is not after Kamal’s stake in ES Ceramics. The question of Kamal selling assets, that is his shares in ES Ceramics, when bankruptcy proceedings have been initiated also adds intrigue to the mystery of the shareholding changes at ES Ceramics.

疫苗接种如火如荼 手套股挫跌后显露价值

 


报道:林志斌

(吉隆坡24日讯)冠病疫苗来到大马,手套股顿时失宠,本月已经下挫超过20%,不过市场专家认为,手套股已经跌出投资价值。

据彭博社报道,Northcape资本基金经理罗斯卡梅伦直呼,手套股的基本面依然强劲,但估值却跌至10年来最低。

“经济重启的气氛无疑影响了市场情绪,但手套股的基本面仍然强。”

卡梅伦甚至指出,在当前的超低估值下,以顶级手套(TOPGLOV,7113,主板保健股)为代表的手套股,“是世上派发最高周息率的股票之一”。

顶级手套于上个月宣布,本财年接下来的季度,将在现有净利的50%派息率政策基础上,再额外追加20%作为特别股息派发。

4手套股挫约8%

大众投行研究分析师据此预计,该公司今年估计派息最少每股74.3仙,若以今日5.23令吉闭市价计算,这可换算为14.21%周息率!

手套股今年以来遭到严重的抛售与卖压,过去5个交易日,除了高产柅品工业(KOSSAN,7153,主板保健股)周一(22日)稍微反弹之外,手套“四大天王”股价皆一路向南。

首相丹斯里慕尤丁和卫生总监丹斯里诺希山等人今日接种疫苗,更成为手套股的催命符,四支手套股今日皆下挫约4至8%。

其中,去年疫情的最大赢家速柏玛(SUPERMX,7106,主板保健股)的股价,本月迄今已下挫约24%,估值更是跌至未来一年净利预测的4.8倍本益比。

顶级手套股价本月同样跌了22%,目前处于未来一年6倍本益比的低谷,创下历史最低估值记录;去年5月时,该股的未来一年本益比高达43倍。

林伟才再回购

此外,贺特佳(HARTA,5168,主板保健股)的股价也低于未来一年本益比10倍;高产柅品则处于4.2倍。

彭博社也统计,手套“四大天王”的市值单单在2月,总共就蒸发了超过50亿美元(202亿令吉)。

手套股今日狂泻,顶级手套执行主席丹斯里林伟才今日再出手扶盘;根据交易所文件显示,林伟才今日购入377万股自家股票,占据总股数的0.046%。

至今,他通过直接和间接,共持有35.019%顶级手套的股权。

市场转向疫苗股

随着疫苗的面市,全球资金已出现大幅度转移;彭博社的报道就指出,我国手套股与多家“疫情概念股”一样,近数个月来都遭到大幅度抛售。

其中,韩国的诊断产品制造商Seegene公司,以及采用皮下注射技术的生物技术公司Alteogen公司,在疫苗面市之后,股价也都下挫超过40%。

然而,市场总是一家欢喜一家愁;在疫情概念的医疗保健相关股项纷纷下挫的同时,取而代之的是疫苗相关股项的涨风。

其中,生产疫苗的美国辉瑞(Pfizer)、BioNTech,以及Moderna,就成为市场新宠;而深圳迈瑞医疗创始人李西廷,更跃升成为新加坡首富。

报道同时也指出,并非所有“疫情概念股”都因为这场转变而受到影响,那些受益于封城锁国及居家工作的科技股项,如亚马逊以及Zoom,股价就依然坚挺。

黄德顺失10亿美元富豪地位

不过,在新加坡上市的立合斯顿控股(Riverstone Holdings),今年表现仍算顽强,开年以来股价已走高20.72%。

惟该股今日依然敌不过手套股的下跌情绪,单日下跌了新币4仙或2.90%,以1.34新元报收。

而且根据彭博社的记录,去年7月,立合斯顿联合创办人黄德顺,身家一度高涨至12亿美元(约48.51亿令吉),晋身10亿美元富豪俱乐部。

然而,随着手套股从高点回落,黄德顺目前的身家也已跌破了十亿美元。

根据本报最新统计,黄德顺身家财富为30.9亿令吉或约7.7亿美元左右。

2021年2月21日星期日

Rubber glove factory in South in flames


  •  
  •  
  •  
A fire is seen at a factory Sri Trang Gloves (Thailand) in Kanchanadit district of Surat Thani on Sunday. (Photo by Supapong Chaolan)
A fire is seen at a factory Sri Trang Gloves (Thailand) in Kanchanadit district of Surat Thani on Sunday. (Photo by Supapong Chaolan)

SURAT THANI: A fire broke out at a rubber glove factory in Kanchanadit district of this southern province on Sunday afternoon. There were no reports of deaths or injuries.

Pol Capt Tawatchai Sak-amnuay, a duty officer at Kanchanadit police station, said the factory at Moo 7 village on Surat Thani-Nakhon Si Thammarat road in tambon Phlai Wat belongs to Sri Trang Gloves (Thailand) Company.

The factory is located behind a building under construction.

Seven fire engines from the Surat Thani and other municipalities were rushed to combat the fire under the supervision of Jamnong Sawatwong, chief of the provincial disaster prevention and mitigation office.

The fire was brought under control after nearly two hours. No deaths or injuries were reported. The damage was yet to be assessed.

The cause of the fire was being investigated.

Fret not for Malaysia’s GLOVEs ‘still has legs to run’

 


Author:    |    Publish date: 


{{{PM me to join GLOVE Private Discussion Room}}}

I invite you to read my blog and make a smart GLOVE decision.

https://klse.i3investor.com/blogs/gloveharicut/blidx.jsp

 

I am reproducing the Focus Malaysia Article to my blog.

This post don't have any value added content.

Compile here for my own record.

Please skip if you don't like it.

 

https://focusmalaysia.my/markets/fret-not-for-malaysias-rubber-glove-sector-still-has-legs-to-run/

Fret not for Malaysia’s rubber glove sector ‘still has legs to run’

 
 
 

SENTIMENT towards the glove sector has doubtlessly changed – as evident on the stock price regression of the Big Four glove counters – given the rapid development on the COVID-19 vaccine scene.

Some investors have increasingly shifted their focus to recovery beneficiaries which has led share price correction of glove stocks across the board on Bursa Malaysia.

On the other hand, most glove companies expect 2021 to be a stronger year for them due to higher volume as a result of their production expansion coupled with higher average selling prices (ASPs) compared to 2020.

Some players expect sequential quarter ASP growth to continue into 3Q CY2020. While this is possible, MIDF Research opined that the rise will be at a smaller quantum due to the high-base effect.

“ASPs have more than doubled in 2020 compared to 2019,” the research house pointed out in a thematic report that focuses on the glove sector.

“We do not discount the possibility of softening blended ASPs in the second half when urgent sales start to soften.”

This is more likely to impact the spot price segment which is usually quoted at a higher selling price compared with contract orders. That said, the research house does not expect ASPs to decline sharply because demand may continue to exceed supply.

“With industry players projecting shortage in nitrile gloves that could possibly last until 2023 due to the shortage in raw material supply, ASPs for rubber gloves are expected to remain robust in the next 18 to 24 months,” projected MIDF Research.

“We view that high raw material prices will lend support to ASP of nitrile gloves.”

While industry players are expanding at a faster pace to keep up with demand, the research house reckoned that this is not done without challenges.

Other than the shortage in nitrile rubber, the industry is also facing labour shortage due to the closure of international borders.

The established glove players expect to further automate their processes in order to reduce number of workers per million pieces.

“The four companies under our coverage expanded by an estimated 21% in CY2020 compared to the preceding year when demand growth was estimated at 25%,” observed MIDF Research.

“Production challenges are among the main reasons why industry players foresee that demand will exceed supply in the near future.”

Going forward, the research house acknowledged that companies under its coverage are looking to further improve their products and manufacturing processes through research & development (R&D) as well as sharpening their business strategies.

All-in-all, MIDF Research maintained its positive view on the sector as it believes that demand growth will continue after the COVID-19 pandemic.

“Malaysia supplies about 65% of the world’s total rubber gloves which means collectively, Malaysian glove companies have market leader advantages,” justified the research house.

“The mature ecosystem in the country which has been built over a period of more than three decades, is expected to allow the established players to continue to remain efficient and competitive in the long term.”

On this note, MIDF Research maintained its “buy” recommendations on all the Big Four glove makers – Hartalega Holdings Bhd (target price: RM18.25), Top Glove Corp Bhd (TP: RM8.29), Kossan Rubber Industries Bhd (TP: RM7.33) and Supermax Corp Bhd (TP: RM13.83). – Feb 19, 2021

GLOVE prices remain robust amid supply shortage

 


“Other than the shortage in nitrile rubber gloves, the industry is also facing a labour shortage due to the closure of international borders, ” the research arm of MIDF Amanah Investment Bank Bhd said in a note yesterday.

 

PETALING JAYA: The average selling price (ASP) of rubber gloves is expected to remain robust in the next one-and-a-half to two years, since industry players are projecting a shortage in nitrile gloves that could possibly last until 2023 due to the shortage in raw material supply, MIDF Research said.

The high raw material prices will lend support to the price of nitrile gloves, it said.

“Industry players are expanding at a faster pace to keep up with demand, but it is not done without challenges.

“Other than the shortage in nitrile rubber gloves, the industry is also facing a labour shortage due to the closure of international borders, ” the research arm of MIDF Amanah Investment Bank Bhd said in a note yesterday.

It noted that the established glove players expect to further automate their processes in order to reduce the number of workers per million pieces.

“Production challenges are among the main reasons why industry players foresee that demand will exceed supply in the near future, ” it added.

“Malaysia supplies about 65% of the world’s total rubber gloves, which means collectively, Malaysian glove companies have market leader advantages.

One notable growth driver of rubber glove demand is higher hygiene awareness in the developing nations, while in the developed countries, demand is driven by more stringent medical processes, an ageing population which leads to higher medical needs, as well as consumption in other services sectors.

“The glove consumption is expected to remain high in 2021. We believe that mass testing and random testing will continue until a wide population is vaccinated.

“This is especially so if economies, social activities, and schools are to reopen while remaining safe. For example, in the US, US$50bil has been allocated to expand testing to buy rapid tests and increase laboratory capacity to support regular testing in schools so that they can safely reopen, ” it said.

The research house also said that industry players also expect high demand for rubber gloves from the massive rollouts of vaccination programmes.

MIDF Research said four companies under its coverage had expanded by an estimated 21% in calendar year 2020 compared to the preceding year when demand growth was estimated at 25%. ─ Bernama

 

https://www.thestar.com.my/business/business-news/2021/02/19/glove-prices-remain-robust-amid-supply-shortage

Medical glove exports face more delays amid shipping container shortage


Author:    |    Publish date: 


KUALA LUMPUR (Reuters) - Malaysia's medical glove makers face weeks of delays in delivering products to customers abroad due to a global shortage of shipping containers, hampering their ability to meet demand during the coronavirus crisis, industry officials said.

Supramaniam Shanmugam, president of the Malaysian Rubber Glove Manufacturers Association (MARGMA), told Reuters on Friday the container shortage had eased after year-end festivities but the situation had yet to return to normal, with exports by glove makers still facing delays of two to five weeks.

 

Malaysia, the world's biggest producer of medical gloves, has been racing to meet skyrocketing demand due to the pandemic.

MARGMA said the lead time to deliver gloves to customers had increased by more than six months even as manufacturers ramped up production to cope with new orders.

Industry officials say the situation could return to normal by the end of February, after previously estimating export delays could continue until March.

"There are more empty containers available now. However, there may not be enough vessel space and we need to manage this till February," Shanmugam said.

China saw a container crunch at the end of last year, sending cargo costs to record highs and hampering the ability of manufacturers to meet fast-recovering global goods orders.

The Malaysian National Shippers' Council said its members faced severe container shortages in the second half of last year and were still scrambling to secure space on vessels. It does not see the situation easing this quarter.

The shortage drove up freight rates by 300%-400%. The council's Chairman Andy Seo said higher rates were becoming the benchmark with exporters ready to pay a premium.

"Members have indicated that container booking requests get cancelled by the shipping lines at the very last minute unless manufacturers were able to pay higher freight rates, he said.

 

https://www.thestar.com.my/business/business-news/2021/01/15/medical-glove-exports-face-more-delays-amid-shipping-container-shortage

Pfizer vaccine appears effective against coronavirus variant found in Britain — study

 


Pfizer vaccine appears effective against coronavirus variant found in Britain — study

FRANKFURT (Jan 20): The Covid-19 vaccine developed by Pfizer and BioNTech is likely to protect against a more infectious variant of the virus, which was discovered in Britain and has spread around the world, according to results of further lab tests released on Wednesday.

The encouraging results from an analysis of blood of participants in trials are based on more extensive analysis than those released by the US drug maker last week.

Last week, Pfizer said a similar laboratory study showed the vaccine was effective against one key mutation, called N501Y, found in both of the highly transmissible new variants spreading in Britain and South Africa.

The latest study, posted on bioRxiv.org but not yet peer-reviewed, was conducted on a synthetic virus with 10 mutations that are characteristic of the variant known as B117 identified in Britain.

Among the 11 authors of the study are Ugur Sahin and Oezlem Tuereci, co-founders of BioNTech. Sahin is chief executive and his wife Tuereci is chief medical officer.

It provides further hope as record numbers of daily deaths from Covid-19 are reported in Britain, which is believed to be driven by the more transmissible variant. It also means vaccine development would for now not have to start all over again.

For the test, blood samples drawn from 16 vaccinated participants in prior clinical trials were exposed to a synthetic virus called pseudovirus, which was engineered to have the same surface proteins as B117, as characterised by 10 hallmark mutations.

The antibodies in the blood of the volunteers given the vaccine, known as Comirnaty, or BNT162b2, neutralised the pseudovirus as effectively as the older coronavirus version that the product was initially designed for.